Superselective uterine arterial embolization with pingyangmycin-lipiodol emulsion for management of symptomatic uterine leiomyoma.
BACKGROUND
Uterine arterial embolization (UAE) is a safe and effective therapy for symptomatic uterine leiomyoma. This study was to assess the effectiveness and the feasibility of pingyangmycin-lipiodol emulsion (PLE) for the management of symptomatic uterine leiomyoma.


METHODS
One hundred consecutive patients (aged 21 - 53 years, with 38 in average) with symptomatic uterine leiomyoma underwent superselective UAE with PLE. Clinical symptoms of the patients (including menorrhagia, bulk-related symptoms, and postprocedure-related abdominal pain) and the changes in uterine volume and tumor size after the embolization were analyzed. The patients were followed up for 8 - 21 months (mean, 15 months).


RESULTS
Ninety-nine patients (99%, 99/100) were interviewed in their first menses circle after embolization, showing improvements in their abnormal bleeding and bulk-related symptoms to some extent. Imagiological results during follow-up showed a mean of 48% reduction in uterine volume at 6 months and a mean of 75% reduction in tumor size at 9 months. Eighty-three percent of the patients reported complete resolution of postprocedure pain within 7 days.


CONCLUSIONS
PLE is effective in the management of uterine leiomyoma, having superiority in alleviating postprocedure-related pain.
Shan
Hong
H
Department of Radiology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. gzshsums@public.guangzhou.gd.cn
Huang
Ming-sheng
MS
Guan
Shou-hai
SH
Jiang
Zai-bo
ZB
Zhu
Kang-shun
KS
Li
Zheng-ran
ZR
D000328:Adult; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D003287:Contrast Media / Q000008:administration & dosage*; D004621:Embolization, Therapeutic / Q000379:methods*; D004655:Emulsions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage*; D007889:Leiomyoma / Q000628:therapy*; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000628:therapy*; D014599:Uterus / Q000098:blood supply
D000903:Antibiotics, Antineoplastic; D003287:Contrast Media; D004655:Emulsions; D001761:Bleomycin; C021771:zhengguangmycin; D007459:Iodized Oil